Competitive antagonist differs from non-competitive in all the following except:a.It modifies drug potency, not efficacyb.Its effect can be reversed by increasing the dose of the agonistc.It reduces the maximal agonist response even with increasing the dosed.Shift the dose-response curve of the agonist to the right

The statement "Competitive antagonist differs from non-competitive in all the following except" implies that one of the options provided is a characteristic shared by both competitive and non-competitive antagonists. Let's go through each option:

a. It modifies drug potency, not efficacy: This is a characteristic of competitive antagonists. They bind to the same site as the agonist, which increases the amount of agonist needed for the same effect (i.e., it modifies the potency). However, the maximum effect (efficacy) can still be reached if enough agonist is present.

b. Its effect can be reversed by increasing the dose of the agonist: This is also a characteristic of competitive antagonists. Because they compete for the same binding site, increasing the amount of agonist can outcompete the antagonist and reverse its effect.

c. It reduces the maximal agonist response even with increasing the dose: This is a characteristic of non-competitive antagonists. They bind to a different site than the agonist and change the receptor's response to the agonist. This means that even if the amount of agonist is increased, the maximum response is still reduced.

d. Shift the dose-response curve of the agonist to the right: This is a characteristic of both competitive and non-competitive antagonists. Both types of antagonists cause a rightward shift in the dose-response curve, indicating that a higher dose of the agonist is needed to achieve the same response.

So, the answer to the question is d. "Shift the dose-response curve of the agonist to the right" is not a way in which competitive antagonists differ from non-competitive antagonists; it is a characteristic shared by both.